LAKE FOREST, Ill., May 13, 2026
Assertio Holdings announced that it has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, in an all-cash transaction valued at approximately $166.4 million. Under the terms of the agreement, Zydus will acquire all outstanding shares of Assertio common stock for $23.50 per share in cash, representing a significant premium for shareholders and marking a major expansion of Zydus’ global pharmaceutical business and specialty oncology portfolio.
The acquisition follows an extensive strategic review process conducted by Assertio’s Board of Directors after competing acquisition proposals emerged earlier in 2026. The board determined that the Zydus proposal constituted a “Superior Proposal” compared with Assertio’s previously announced merger agreement with Garda Therapeutics, citing stronger transaction certainty, higher shareholder value, and favorable execution terms.
According to the companies, the Zydus offer represents a 30.6% premium to Assertio’s original merger agreement with Garda Therapeutics and a 75.8% premium compared with the company’s unaffected share price prior to significant market activity in March 2026.
Zydus Expands Global Specialty Pharma Presence
The acquisition reflects Zydus Lifesciences’ broader strategy of strengthening its global pharmaceutical footprint through targeted acquisitions and expansion into specialty therapeutic markets. Industry analysts noted that the transaction provides Zydus with enhanced commercial capabilities in the United States while broadening its oncology-focused product portfolio and specialty pharmaceutical infrastructure.
Advertisement
Assertio is recognized for its commercial capabilities in specialty pharmaceuticals, particularly within oncology and hospital-focused therapeutic markets. Company leadership stated that the transaction is expected to support continued growth opportunities while providing shareholders with immediate cash value.
Under the terms of the transaction, Zydus will commence a tender offer to acquire all outstanding Assertio shares, after which any remaining shares will be acquired through a second-step merger process at the same purchase price. Upon completion of the acquisition, Assertio’s common stock will no longer trade on the Nasdaq exchange.
The companies indicated that the transaction is expected to close during the second quarter of 2026, subject to customary closing conditions including shareholder participation requirements. No major regulatory approvals are currently expected to delay completion of the transaction.
Healthcare market observers continue to identify cross-border pharmaceutical acquisitions as a major driver of consolidation within the global healthcare sector, particularly as companies seek to expand commercialization infrastructure, therapeutic portfolios, and geographic market access.
Strategic Review Process Delivered Higher Shareholder Value
Assertio’s Board of Directors stated that the company conducted a disciplined and comprehensive evaluation process before approving the Zydus transaction. Board leadership emphasized that the final agreement was selected based on multiple factors including valuation, certainty of financing, execution risk, and long-term shareholder interests.
Unlike some pharmaceutical acquisitions that depend heavily on external financing arrangements, the Zydus proposal reportedly includes no financing contingencies and is fully guaranteed by a creditworthy Zydus entity. The structure was viewed favorably by Assertio leadership because it reduced potential transaction execution risks and strengthened deal certainty.
Industry experts note that certainty of closing has become increasingly important in pharmaceutical M&A transactions as volatile market conditions, financing challenges, and regulatory uncertainty continue to impact healthcare dealmaking globally.
Pharmaceutical M&A Activity Accelerates Globally
The acquisition highlights continued momentum within the pharmaceutical mergers and acquisitions sector, where companies are increasingly pursuing strategic transactions to strengthen innovation pipelines, specialty drug portfolios, and international commercial capabilities.
Healthcare analysts believe Zydus’ acquisition of Assertio demonstrates the growing ambition of Indian pharmaceutical companies to expand their global reach through acquisitions involving specialty pharmaceutical businesses and established U.S. commercial operations.
The transaction also reinforces broader industry trends focused on consolidation within oncology and specialty therapeutics, areas that continue attracting strong investor interest due to high-growth potential and increasing demand for targeted therapies.
Zydus Lifesciences stated that the acquisition aligns with its long-term strategy of expanding international operations while building a diversified healthcare business capable of addressing evolving patient needs across major global pharmaceutical markets.
Source: Zydus Lifesciences, Assertio Holdings, press release
